Introduction
Protein ± protein interactions play important regulatory roles in signal transduction, transcriptional regulation, enzyme catalysis, membrane interactions and cytoskeletal interactions (reviewed in Pawson, 1995) . This diversity of activities is mediated by a relatively restricted number of protein ± protein interacting modules binding to a small number of structural motifs (reviewed in Schlessinger, 1994; Cohen et al., 1995; Pawson, 1995; Birge et al., 1996) . A subset of these modules, such as the Src homology 3 (SH3), WW and Ena/Vasp Homology (EVH1) domains, bind to proline-rich regions on target proteins (reviewed in Kay et al., 2000) . SH3 and WW domain-mediated protein ± protein interactions have been implicated in a number of human diseases such as AIDS, allergy, asthma, cancer, CML, ALL, in¯ammatory diseases, pre-B-cell leukemia, myelodysplastic syndrome, osteoporosis, Liddle's syndrome of hypertension, muscular dystrophy, Alzheimer's and Huntington's (reviewed in Dalgarno et al., 1997; Kay et al., 2000) . These ®ndings suggest the possibility that speci®c inhibitors of SH3 or WW interactions might be therapeutically useful.
The SH3 domain, a noncatalytic protein module composed of approximately 60 amino acids, is found in all eukaryotic organisms (reviewed in Koch et al., 1991; Mayer and Baltimore, 1993; Pawson and Schlessinger, 1993) and perhaps even in bacteria (Ponting et al., 1999) . This ubiquitous distribution suggests the universal importance of SH3 domains (reviewed in Kay et al., 2000) . More than 50 SH3 domains are known to date and these are widely distributed in several classes of proteins, including Src family tyrosine kinases (e.g., Src, Abl, Csk), enzymes (e.g., PLCg, Ras-GAP and p85 subunit of PI3K), tyrosine phosphatases (e.g., PTP1C, Syp), adapter proteins, which in some cases are composed almost exclusively of SH2 and SH3 domains (e.g., Grb2, Nck, Crk) and cytoskeletal proteins (e.g., cortactin, myosin 1B, spectrin) (reviewed in Bar-Sagi et al., 1993; Mayer and Baltimore, 1993; Schlessinger, 1994; Birge et al., 1996) . The surface of the SH3 domain consists of a relatively¯at, aromatic amino acid-rich, hydrophobic patch of approximately 390 A Ê , with three shallow ligand-binding pockets (reviewed in Dalgarno et al., 1997; Mayer, 2001) . Despite the apparent lack of speci®city that one might expect, studies using peptide libraries have shown that SH3 domains exhibit distinct binding preferences (Rickles and Zoller, 1994; Sparks et al., 1994 Sparks et al., , 1996 reviewed in Ladbury and Arold, 2000) .
In general, SH3 domains recognize speci®c amino acid sequences containing proline and hydrophobic residues in target proteins, with a minimal consensus sequence of PxxP (Cicchetti et al., 1992; Ren et al., 1993; reviewed in Sudol, 1998; Kay et al., 2000; Mayer, 2001) . The ligand adopts an extended left-handed helical conformation termed the polyproline-2 (PPII) helix (reviewed in Mayer, 2001) . Given the small size of the target sequence, binding speci®city to this minimal PxxP core is conferred by adjacent amino acids (Sparks et al., 1996) . Proline-rich ligands for SH3 domains fall into two categories. The ®rst category, designated typical proline-rich ligands, can be classi®ed into classes I and II depending on whether an invariant arginine residue, adjacent to the PxxP core sequence, lies N or C-terminally with respect to the core (Feng et al., 1995) . Two of the three ligand-binding pockets of the SH3-domain are occupied by the two hydrophobicproline dipeptides that occur in register on the PPII helix (reviewed in Mayer, 2001 ). The arginine residue in the PxxP core interacts with the third ligand-binding pocket, termed the speci®city pocket in the SH3 domain which ensures that SH3 domains do not interact promiscuously with all proteins containing a PxxP domain (reviewed in Dalgarno et al., 1997; Kay et al., 2000) . A variation on the PxxP theme is encountered in the case of p53 interacting with p53BP2, in which the PxxP domain in p53 does not reside in a contiguous stretch of amino acids, but is instead formed by the overall 3-dimensional structure adopted by the protein (Gorina and Pavletich, 1996) . The second category, designated atypical proline-rich ligands, includes SH3 domain interacting proteins that do not contain the PxxP core (Manser et al., 1998; Mongiovi et al., 1999; Kato et al., 2000; Lewitzky et al., 2001; Nishida et al., 2001) .
Given the importance of SH3-mediated protein ± protein interactions in human disease, much eort has been directed to the identi®cation of inhibitors of this interaction (reviewed in Smithgall, 1995; Dalgarno et al., 1997) . To date, all strategies aimed at disrupting SH3-mediated protein ± protein interactions utilize synthetic peptides based on the native target sequence or peptides selected from screening with degenerate peptide and phage display libraries (reviewed in Smithgall, 1995; Dalgarno et al., 1997; Kay et al., 2000) . All SH3 domain inhibiting ligands reported so far, generally consist of 10 or more amino acids. In addition to peptide ligands, SH3 domain-mediated interaction blocking peptidomimetic and peptoids have been identi®ed (Combs et al., 1996; Nguyen et al., 2000) ; reviewed in Dalgarno et al., 1997) . However, to date, small molecule, non-peptide based inhibitors of SH3 domain-mediated protein ± protein interaction have not been reported.
We previously reported on the unique ability of UCS15A to inhibit Src signal transduction without inhibiting its kinase activity or altering its stability (Sharma et al., 2001) . Our earlier studies had suggested that UCS15A might be exerting its eects by disrupting Src-mediated protein ± protein interactions. In the present study, we have examined the mode of action of UCS15A by studying its eects on SH3-mediated protein ± protein interactions in Src and other SH3 domain containing proteins. Our current studies indicate that UCS15A has the unique ability to disrupt SH3-mediated protein ± protein interactions and that this eect, is in all likelihood, mediated by the direct interaction of the drug with proline-rich domains on target proteins.
Results

Inhibition of the association of c-Src with Sam68 by UCS15A in HCT116 cells
Previous studies have suggested that c-Src interacts with a substrate designated Sam68, speci®cally in mitosis, (Fumagalli et al., 1994; Taylor and Shalloway, 1994) . On the other hand, Src has been shown to associates with Sam68 in a constitutive manner throughout the cell cycle (Pillay et al., 1996) . While Src binding to Sam68 involves both the SH2 and SH3 domains of Src, it has been proposed that Sam68 interacts initially with the SH3 domain of Src and is subsequently tyrosine phosphorylated by Src, speci®-cally during mitosis, and results in the high anity binding of Sam68 to Src via its SH2 domain (Shen et al., 1999) . Previous studies had shown that in v-Src transformed mouse ®broblasts, UCS15A inhibited the tyrosine phosphorylation of Src substrates, such as Sam68 and cortactin and also induced the disruption of the Src ± Sam68 complex (Sharma et al., 2001) . To further investigate the mechanism of action of UCS15A, the eect of the drug on Src-mediated protein ± protein complexes were examined in HCT116 cells (Figure 1 ). Src protein was immunoprecipitated from UCS15A treated HCT116 cells and the tyrosine phosphorylation status of Src and its associated proteins was examined by immunoblot analysis with phosphotyrosine antibody (Figure 1a) . Under the conditions used, several tyrosine phosphorylated proteins were found associated with c-Src in untreated cells (Figure 1a , left panel, lane 1). Upon UCS15A treatment, these tyrosine phosphorylated proteins diminished in a dose-dependent manner ( Figure 1a , left panel, lanes 2 ± 5), albeit with dierent eciencies. Under the same conditions, the tyrosine phosphorylation of Src itself remained relatively unaltered ( Figure 1a , left panel). To examine the association of Src with a speci®c target, Sam68, the ®lter from Figure 1a (left panel) was stripped and reprobed with Sam68 antibody. While Sam68 was associated with c-Src in untreated HCT116 cells (Figure 1a , right panel, lane 1), UCS15A treatment of these cells resulted in a dose-dependent decrease in Src-associated Sam68 itself (Figure 1a , right panel, lanes 2 ± 5). Since cells in the experiment shown in Figure 1a were treated with a relatively high dose of the drug (lowest concentration of 5 mM) and for relatively long periods of time (15 h), treatment with lower doses of the drug (0 ± 20 mM) and for shorter periods of time (2 h) were attempted (Figure 1b, left panel) . As little as 1 mM UCS15A treatment for 2 h (Figure 1b , bottom left panel, lane 2) very eectively disrupted the Src ± Sam68 complex in vivo. Other studies have shown that a similar eect can be seen with as little as 0.5 mM of UCS15A (data not shown). As demonstrated previously (Sharma et al., 2001) , the intracellular level of Sam68 was unaltered by drug treatment (Figure 1b , top left panel). Since there is some ambiguity as to whether Sam68 interacts with Src via its SH2 or its SH3 domain, the mode of interaction of Sam68 with Src, in the HCT116 cell system, was investigated further. To this end HCT116 cell lysates were anity precipitated with either the SH2, SH3 or SH2+SH3 domains of Fyn (Figure 1b , right panel lanes 2, 3 and 4, respectively). As a control, cell lysates extracted under the same conditions were immunoprecipitated with Src antibody (Figure 1b , right panel, lanes 1 and 5). As revealed by immunoblotting with Sam68 antibody (Figure 1b , right panel), Sam68 did not associate with the SH2 domain of Fyn (Figure 1b , right panel, lane 2) but interacted exclusively with the SH3 domain ( Figure 1B , right panel, lane 3). In fact, it is very likely that under the conditions used in this study, the SH2 domain did not contribute at all to the binding of Sam68, since the presence of this domain, even in combination with the SH3 domain, did not enhance the binding ability of the SH3 domain ( Figure  1b , right panel, compare lanes 3 and 4). Taken together, these results suggested that in HCT116 cells, Sam68 associated with c-Src via the SH3 domain of Src. Furthermore, the ability of UCS15A to disrupt this association suggested that the drug disrupted the SH3-mediated interaction of Src with at least one of its substrates, Sam68.
UCS15A is distinct from Src kinase inhibitor such as PP2
Since UCS15A eectively inhibited the tyrosine phosphorylation of c-Src-associated proteins ( Figure  1a , left panel), the possibility that UCS15A could aect the tyrosine kinase activity of c-Src was examined by an in vitro kinase assay, using a synthetic peptide derived from Cdc2, as a Src family speci®c tyrosine kinase substrate (Zhu et al., 1998) . Previous studies had shown that UCS15A did not inhibit the tyrosine kinase activity of v-Src (Sharma et al., 2001) . Since vSrc, used in these studies (pJH v-Src) lacked the Cterminal regulatory tyrosine 527, and was therefore incapable of auto-inhibition, the eect of UCS15A on c-Src was tested in the present studies. The kinase activity of immunoprecipitated c-Src protein was assayed in vitro in the presence of increasing concentrations of either UCS15A or the established Src kinase inhibitor, PP2 (Hanke et al., 1996) , which served as a positive control for the assay (Figure 2b ). As described previously (Hanke et al., 1996) , PP2 eectively inhibited the in vitro kinase activity of c-Src to less than 10% of untreated controls (Figure 2b ). In sharp contrast, UCS15A had no eect on c-Src kinase activity, even at concentrations as high as 20 mM (Figure 2b ). To further ensure that the mechanism of action of UCS15A and PP2 were distinct, the ability of the two compounds to disrupt the Src ± Sam68 complex was examined ( Figure 2a ). As shown previously (Figure 1 ), UCS15A very eectively disrupted the Src ± Sam68 complex in HCT116 cells (Figure 2a , lanes 4 ± 8). On the other hand, the Src-kinase inhibitor PP2 had no eect on the Src ± Sam68 complex, even at concentrations as high as 10 mM (Figure 2a, lanes 1 ±  4) . These results very conclusively demonstrated that UCS15A was a very dierent kind of Src inhibitor and that its mode of action was distinct from that of more conventional tyrosine kinase inhibitors such as PP2.
UCS15A disrupts the association of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCg
The ®nding that UCS15A disrupted the association of Sam68 and Src (Figure 1) , together with the ®nding that the interaction of Sam68 with c-Src was SH3-mediated (Figure 1b) , suggested the possibility that the drug may disrupt the association of Sam68 with other SH3 domain containing proteins. Previous studies have suggested that in addition to c-Src, Sam68 can bind to several other proteins such as phosphatidylinositol 3-OH kinase, phospholipase C-g (PLCg) and Grb2 (Fusaki et al., 1997; Jabado et al., 1998) , via their SH3 domains (Shen et al., 1999) in vivo and in vitro (Richard et al., 1995; Taylor et al., 1995; Finan et al., 1996; Shen et al., 1999) . Therefore, the eect of UCS15A on Sam68 association with PLCg and Grb2 was examined (Figure 3 ). PLCg or Grb2 protein was immunoprecipitated from UCS15A treated HCT116 cells and the associated Sam68 protein was examined by immunoblot analyses with Sam68 antibody ( Figure  3a) . As expected, Sam68 was found associated with PLCg and Grb2 in untreated cells (Figure 3a , lanes 1 and 5, respectively). After treatment of the cells with UCS15A, the association of Sam68 with PLCg and Grb2 decreased in a dose-dependent manner, albeit with slightly dierent eciencies. The Grb2 ± Sam68 complex was much more sensitive to disruption by cell lysates were incubated with Sam68 antibody as positive control (lanes 1 and 9), or agarose conjugated beads attached to either the full-length (SH3/2/3), the N-terminal SH3 domain (SH3 (N)), the SH2 domain, or the C-terminal SH3 domain (SH3 (c)) of Grb2 (lanes 2, 3, 4 and 5, respectively) or the two SH2+SH3 domains (SH2/2/3), the SH3 domain, or the two N-terminal SH2 domains (SH2/2) of PLCg (lanes 6, 7 and 8 respectively) at 48C for 15 h. Immunoblots of the immunoprecipitated or anity precipitated proteins were probed with Sam68 antibody. The position of migration of Sam68 is indicated to the right of autoradiograms A and B. Approximate molecular weights of standards are indicated in kilodaltons to the left of autoradiogram A and B UCS15A than was the PLCg ± Sam68 complex ( Figure  3a , compare lanes 2 ± 4 for PLCg with lanes 6 ± 8 for Grb2). To better understand the reason for this discrepancy, the mode of association of Sam68 with Grb2 and PLCg was investigated ( Figure 3b ). Sam68 associated exclusively with the N-and C-terminal SH3 domains of Grb2 ( Figure 3b , lanes 3 and 5) but not with the SH2 domain of Grb2 ( Figure 3b , lane 4). The binding to the isolated N-and C-terminal SH3 domains was more ecient than the binding to a polypeptide containing all three modules i.e., SH3/2/3 ( Figure 3b , lane 2). Taken together, these results suggested that the association of Sam68 with Grb2 was a simple interaction involving SH3 domains exclusively. On the other hand, the association of Sam68 with PLCg was more complex since neither the isolated SH3 domain (Figure 3b , lane 7) nor the 2 SH2 domains ( Figure 3b , lane 8) were capable of binding Sam68. However, a combination of SH2/2/3 domains was capable of binding to Sam68 (Figure 3b , lane 6), suggesting that the binding of Sam68 to PLCg in this system may be complex. The dierences in the modes of binding of Sam68 to Grb2 and PLCg ( Figure 3b ) might explain the observed dierences in the ability of UCS15A to disrupt the complexes in vivo (Figure 3a ). Despite the minor dierences observed, these results suggested that UCS15A disrupted the association of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCg and served to highlight the wide-spread ability of UCS15A to disrupt SH3-mediated protein ± protein interactions.
UCS15A disrupts other typical SH3-mediated protein ± protein associations such as cortactin ± ZO1 and Grb2 ± Sos1 as well as atypical SH3-mediated interactions such as Grb2 ± Gab1
The ®nding that UCS15A was capable of disrupting the association of Sam68 with a variety of SH3 containing proteins such as c-Src, PLCg and Grb2, suggested the possibility that the drug may exert a similar eect on other SH3-mediated protein ± protein interactions. Although most SH3 domains interact with proteins containing the canonical P-x-x-P motif (termed typical proline-rich domains), some SH3 domains can bind to proteins that do not have the Px-x-P motif (termed atypical proline-rich domain) (reviewed in Mayer, 2001) . To further investigate the eects of UCS15A on SH3-mediated protein ± protein interactions, other sets of SH3-mediated protein ± protein complexes (besides those involving Src and Sam68) were investigated. To this end, the cortactin ± ZO1 complex, which involves the interaction of an SH3 domain with a typical proline-rich sequence, was chosen as an example of an SH3-mediated interaction that is important in cytoskeletal organization (reviewed in Tsukita et al., 1999) . Previous studies have shown that the SH3 domain of the actin-binding protein, cortactin, interacts with a P-x-x-P motif in the prolinerich domain of ZO1 (Katsube et al., 1998) . In the experiment shown in Figure 4A , cortactin protein was immunoprecipitated from UCS15A treated HCT116 cells and the associated ZO1 protein was examined by immunoblot analyses with ZO1 antibody. As reported previously (Katsube et al., 1998) , ZO1 associated with cortactin ( Figure 4a , upper panel, lane 2) and could be detected by immunoblotting with ZO1 antibody, which also recognized the 160 kilodalton related protein, ZO2 (Figure 4a, top panel, lanes 1 and 8) . Upon UCS15A treatment, the level of cortactin-associated ZO1 diminished in a dose-dependent manner, especially between 2 and 5 mM and was virtually abolished at 10 mM of UCS15A (Figure 4a, upper panel) . The levels of cortactin remained relatively unchanged, upon UCS15A treatment (Figure 4a, lower panel) . These results suggested that UCS15A was capable of disrupting the SH3-mediated interaction between the cytoskeletal proteins, cortactin and ZO1.
The N-and C-terminal SH3 domains of Grb2 bind constitutively to proline-rich regions in the guanine nucleotide exchange factor Sos1 (Gale et al., 1993; Li et al., 1993; Rozakis-Adcock et al., 1993) . To investigate the eect of UCS15A on the Grb2 ± Sos1 complex, Grb2 protein was immunoprecipitated from UCS15A treated HCT116 cells and Sos1 associated with Grb2 was examined by immunoblot analyses with Sos1 antibody (Figure 4b , upper panel). As expected, Sos1 associated with Grb2 in untreated cells (Figure 4b , upper panel, lane 2). Upon UCS15A treatment, Sos1 association with Grb2 decreased in a dose-dependent manner, albeit less eciently than in the case of Sam68 associated with Grb2 ( Figure 4B, lower panel) .
Thus far, all the SH3-mediated protein ± protein interactions analysed involved typical proline-rich domains containing the canonical P-x-x-P motif. To examine the eect of UCS15A on an SH3-mediated protein ± protein interaction that involved an atypical proline-rich domain, the eect of UCS15A on the Grb2 ± Gab1 complex was examined (Figure 4c) . Previous studies have shown that Gab1 interacted with the C-terminal SH3 domain of Grb2 via an atypical proline-rich core sequence, P-x-x-x-R-x-x-K-P instead of the typical P-x-x-P motif (Lewitzky et al., 2001) . To investigate the eect of UCS15A on the Grb2 ± Gab1 complex, Grb2 protein was immunoprecipitated from UCS15A treated HCT116 cells and the associated Gab1 protein was examined (Figure 4c, upper panel) . As reported previously (Schaeper et al., 2000) , Gab1 associated with Grb2 in untreated cells (Figure 4c , upper panel, lane 2). Upon UCS15A treatment, Gab1 association with Grb2 decreased in a dose-dependent manner, albeit less eciently than in the case of Sam68 associated with Grb2 ( Figure 4c , lower panel). Taken together with the results shown in Figure 4a and b, these results suggested that UCS15A was able to disrupt SH3-mediated interactions that are mediated by both typical (P-x-x-P) as well as at least one atypical (P-x-x-x-R-x-x-K-P) proline-rich sequence. These studies point to the widespread ability of UCS15A to disrupt SH3-mediated protein ± protein interactions and raises the possibility that it may in fact be universal.
UCS15A does not disrupt non-SH3-mediated protein ± protein interactions of b-catenin with E-cadherin and a-catenin
The results thus far suggested that UCS15A was able to disrupt all SH3-mediated protein ± protein interactions examined. One concern was that UCS15A might be a general protein ± protein interaction disrupting agent. Therefore, we focused our attention on protein ± protein interactions that were not mediated by SH3 domains. Previous studies have demonstrated that bcatenin associates with the cytoplasmic domain of Ecadherin via its internal armadillo repeats (Hulsken et al., 1994; Huber and Weis, 2001 ). In addition, the Nterminal armadillo repeats of b-catenin associate with a-catenin, which in turn binds directly with F-actin (Pai et al., 1996) . E-cadherin, a-and b-catenin do not have any SH3 domains and the associations among them are thus, not SH3-mediated. Therefore, the eect of UCS15A on the E-cadherin/a-/b-catenin protein complex was examined ( Figure 5 ). To this end, the Ecadherin protein was immunoprecipitated from UCS15A treated HCT116 cells and the associated aor b-catenin was examined by immunoblot analyses with a-catenin or b-catenin antibody ( Figure 5 top left and bottom panels, respectively). As expected, a-and b-catenin associated with E-cadherin in untreated HCT116 cells ( Figure 5 top and bottom panels, lane 1). However, UCS15A treatment had virtually no eect on the complex even at concentrations as high as 20 mM ( Figure 5 top and bottom panels, lanes 2 ± 6). A parallel experiment showed that under the same experimental conditions UCS15A was able to disrupt the SH3-mediated interaction between Grb2 and Sam68 in a dose-dependent manner ( Figure 5 , top panel, lanes 7 ± 9). Taken together, these results clearly indicated that UCS15A did not disrupt the non-SH3-mediated protein ± protein interactions of b-catenin with E-cadherin and a-catenin and suggested that the protein ± protein interaction disrupting ability of UCS15A may be restricted to SH3-mediated interactions.
UCS15A does not disrupt the SH2-mediated protein ± protein interactions between Grb2 and activated epidermal growth factor receptor
In growth factor-mediated signaling, the adapter protein, Grb2 links receptor tyrosine kinases to Rasdependent signaling, by interacting simultaneously with Sos1 through its SH3 domain and with the tyrosineautophosphorylated growth factor receptors via its SH2 domain (Gale et al., 1993; Li et al., 1993; RozakisAdcock et al., 1993) . Thus, in EGF stimulated cells, the Grb2 adapter forms a three-way complex with tyrosine-autophosphorylated EGF-R and Sos1 via its SH2 and SH3 domains, respectively. This therefore aorded us the unique opportunity to test the speci®city of UCS15A by examining its eect simultaneously on the SH2-and SH3-mediated interactions of Grb2 in EGF-stimulated cells. To this end, serumstarved HCT116 cells were stimulated with EGF in the presence of UCS15A. The Grb2 protein was immunoprecipitated from these cells and the associated EGF-R protein (SH2-mediated interaction) and Sam68 (SH3-mediated interaction) were analysed in the same Grb2 immunoprecipitates. Sam68 was analysed instead of Sos1 because Sos1 and the EGF-R have similar molecular weights and would complicate the Western blot analyses. As described previously (Lowenstein et al., 1992) , EGF-R associated with Grb2 speci®cally upon EGF-stimulation ( Figure 6, top panel, lanes 2, 3) . This SH2-mediated interaction between Grb2 and EGF-R was relatively unaected by the presence of up to 10 mM UCS15A (Figure 6 , top panel, lanes 3 ± 5). Subsequently, the same blot was probed with Sam68 to monitor the eect of UCS15A on the SH3-mediated interaction of Grb2 with Sam68. As shown in the bottom panel, Sam68, like Sos1 was constitutively associated with Grb2, even in serum-starved cells ( Figure 6 , bottom panel, lane 2), and its association with Grb2 remained unchanged upon serum stimulation ( Figure 6 , bottom panel, lanes 2 and 3). However, unlike EGF-R, the interaction between Sam68 and Grb2 was inhibited by UCS15A in a dose-dependent manner ( Figure 6 , bottom panel, lanes 4, 5, compare the signals between EGFR and Sam68). The residual signals from the ®rst blotting with EGF-R are visible on the blot (Figure 6 , bottom panel). These results suggested that UCS15A did not have a signi®cant eect on SH2-mediated protein ± protein interactions and, taken together with the other results of this study, strengthens the possibility that UCS15A is a speci®c disrupter of SH3-mediated protein ± protein interactions.
Effects of UCS15A on SH3-mediated interaction in an in vitro assay
Given the ability of UCS15A to speci®cally disrupt diverse SH3-mediated protein ± protein interactions in vivo, further in-depth analyses were undertaken using an in vitro system consisting of just two recombinant proteins, namely, the SH3 domain of Fyn and the proline-rich domains P4 and P5 from the C-terminal region of Sam68. Previous studies have shown that the C-terminal proline-rich domains (P4 and P5) of Sam68 are important for its interaction with Src (Finan et al., 1996; Shen et al., 1999) . The two polypeptides, designated Fyn-SH3 AC (Fyn-SH3) and GST ± Sam68DC (Sam68DC) were produced in E. coli as fusion proteins with Glutathione S-transferase (GST) and their structures are schematically shown in Figure  7a . This highly pure in vitro system was chosen since it allowed the examination of the eects of UCS15A on SH3-mediated protein ± protein interactions in the absence of other interfering factors and could help resolve the question of whether the eects of the drug were direct or indirect. To establish the conditions of the in vitro assay system, two parameters, namely, temperature-and dose-dependence of the eect of UCS15A on SH3-mediated interaction were ®rst examined ( Figure 7b ,c, respectively). Two dierent reaction temperatures were tested: 48C ( Figure 7b , lanes 1 ± 3) and 258C ( Figure 7b , lanes 4 ± 6). The two recombinant proteins, Fyn ± SH3 and Sam68DC, were incubated with dierent concentrations of UCS15A at the two dierent temperatures (as indicated at the top of each lane in Figure 7b ). Sam68DC protein associated with the Fyn ± SH3 beads under the dierent conditions, was analysed by SDS ± PAGE followed by immunoblotting with GST antibody ( Figure 7B ). As expected, in the absence of UCS15A, Sam68DC associated with Fyn ± SH3, at both temperatures tested (Figure 7b, lanes 1 and 4) . In the presence of the drug, UCS15A induced a dose-dependent decrease in Sam68DC associated with Fyn ± SH3 and this decrease was more or less equivalent at both temperatures ( Figure 7b , lanes 2,3,5,6). Given the relatively high concentration of the drug necessary to observe the disruption of the SH3-mediated protein ± protein interaction in vitro (500 mM) relative to in vivo (1 mM as shown in Figure 1b) , the dose-dependency of UCS15A for disrupting the interaction between Sam68DC and Fyn ± SH3 beads was examined in vitro ( Figure 7c ). The results indicated that the eect of UCS15A in vitro occurred between 100 to 200 mM (Figure 7c , lanes 3 and 4). Taken together, these data indicated that the UCS15A-mediated disruption of the SH3-proline rich domain interaction could be recreated in vitro in a speci®c and dose-dependent manner and further supported the hypothesis that it was due to the ability of the drug to directly aect the protein ± protein complex. However, in vitro disruption of SH3-mediated protein ± protein interaction by UCS15A, required approximately 100 times more drug than in vivo.
UCS15A binds to proline-rich domain containing protein such as Sam68
The ®nding that the UCS15A-mediated disruption of protein ± protein interactions via SH3-domains could be reproduced in vitro (Figure 7 ) allowed further investigation of the mechanistic details of this process (Figure 8 ). To ascertain whether UCS15A blocked the formation of the SH3-proline rich domain complex or could disrupt a pre-existing complex, the complex between Fyn-SH3 and Sam68DC was allowed to form ®rst in vitro and subsequently, various concentrations of UCS15A were added to this pre-formed complex (Figure 8 , lanes 7 ± 9). Under these conditions, even a very high concentration of UCS15A (500 mM) was unable to disrupt the pre-formed complex between Fyn-SH3 and Sam68DC (Figure 8 , lane 9). This was in sharp contrast to the situation where 200 mM of UCS15A very eectively blocked the formation of the protein ± protein complex when added to unassociated Fyn-SH3 and Sam68DC (Figure 7c , lane 4). Taken together, these results suggested that the drug was incapable of disrupting the Src ± Sam68 complex but was capable of inhibiting its formation, at least in vitro. This inhibition by UCS15A could potentially be mediated by the binding of the drug directly to either the SH3 domain of Src/Fyn or the proline-rich domain of Sam68, and consequently interfering with SH3-mediated protein ± protein interactions. In an attempt to resolve whether UCS15A bound to the SH3 domain of Fyn/Src or the proline-rich domain of Sam68, the Fyn-SH3 beads were ®rst incubated with various concentrations of UCS15A for 6 h at 258C ( Figure  8a , lanes 1 ± 3). The drug treated Fyn-SH3 beads were subsequently incubated with Sam68DC for 12 h at 48C, after which they were washed and analysed by immunoblotting with GST antibody (Figure 8a , lanes 1 ± 3). Under these conditions, UCS15A failed to block the interaction between Fyn-SH3 and Sam68DC, suggesting that UCS15A probably does not bind to the SH3 domain of Src/Fyn. On the other hand, when the converse experiment was performed, and Sam68DC protein was ®rst incubated with various concentrations of UCS15A followed by the addition of Fyn-SH3 beads (Figure 8a , lanes 4 ± 6), UCS15A very eectively blocked the interaction between Fyn-SH3 and Sam68DC. Taken together these results suggested that the UCS15A-mediated blockade of SH3-mediated protein ± protein interactions probably resulted from the direct interaction of the drug with the proline-rich domains of Sam68. To further con®rm this hypothesis, the experiment shown in Figure 8b was performed. In this case, the individual protein modules, Sam68DC and Fyn-SH3 were ®rst incubated with dierent concentrations of UCS15A. Subsequently, the unbound drug was removed by centrifugal ®ltration of the samples through Centricon 10. The drug-treated protein modules were then incubated with their complementary protein modules conjugated to Agarose beads. The beads, together with their associated proteins were then washed and analysed by SDSpolyacrylamide gel electrophoresis and Western blotting using GST antibody. UCS15A was able to block the formation of the Sam68DC ± Fyn-SH3 complex only when UCS15A was ®rst incubated with the Sam68DC protein ( Figure 8b , lanes 1 ± 3). This was evidenced by a decrease in the amount of Sam68DC that could be recovered by the Fyn-SH3 beads ( Figure  8B , lanes 1 ± 3). On the other hand, when UCS15A was ®rst incubated with the Fyn-SH3 protein module, UCS15A was unable to block the formation of the Sam68DC ± Fyn-SH3 complex. There was no decrease in the amount of Fyn-SH3 that could be recovered by the Sam68DC beads ( Figure 8b , lanes 4 ± 6).
In the experiments shown in Figures 7 and 8 , both proteins (Fyn-SH3 and Sam68DC) were prepared as GST fusion proteins. Crystallographic analyses suggest that GST has the potential to dimerize (Parker et al., 1990; Reinemer et al., 1991; Ji et al., 1992) . Therefore, it was important to ensure that the observed interaction in vitro was mediated by SH3, and not by GST. To this end, the in vitro system was modi®ed so that at least one of the interacting proteins was not a GST fusion protein. The eect of UCS15A on the association of recombinant SH3 domain of Fyn (a GST containing protein; schematically shown in Figure  6a ) with endogenous Sam68 from cell lysates was examined. As shown in Figure 9a (left panel), Fyn-SH3 beads were able to bind to endogenous Sam68 ( Figure  9a , left panel, lane 2) and this binding was inhibited in a dose-dependent manner by UCS15A (Figure 9a , left panel, lanes 2 ± 6). GST protein alone showed a very low level of background binding to Sam68 (Figure 9a , left panel, lane 1). It is noteworthy that, in contrast to the previous in vitro studies utilizing two GST fusion proteins (Figures 7 and 8) , in the modi®ed system, signi®cantly less UCS15A was required to inhibit the interaction between Fyn-SH3 and intact Sam68 Figure 8 Binding of UCS15A to the SH3 or proline-rich domains. (a) Dierent concentrations of UCS15A were incubated for 6 h at 258C with either Fyn-SH3 AC beads (lanes 1 ± 3) or Sam68DC (lanes 4 ± 6) as indicated at the top of each lane. Subsequently, either Sam68DC (lanes 1 ± 3) or Fyn-SH3 AC beads (lanes 4 ± 6) were added to the reactions and incubated for 12 h at 48C. In lanes 7 ± 9, dierent concentrations of UCS15A were added to pre-formed complex between Fyn-SH3 and Sam68DC. After washing, the anity precipitates with Fyn-SH3 AC beads were separated by SDS ± PAGE, transferred to nitrocellulose membranes and probed with GST antibody. (b) Dierent concentration of UCS15A were incubated overnight at 48C with either Sam68DC protein (lanes 1 ± 3) or Fyn-SH3 (lanes 4 ± 6) as indicated at the top of each lane. Subsequently, unbound UCS15A was removed by ultra®ltration after which each protein was incubated with its complementary protein, namely, Fyn-SH3 (lane 1 ± 3) or Sam68DC (lane 4 ± 6) conjugated to Agarose beads and incubated overnight at 48C. The anity precipitates were resolved by SDS ± PAGE, transferred to nitrocellulose membranes and probed with GST antibody. Positions of migration of Sam68DC and Fyn-SH3 are indicated in the right-hand margin of the autoradiograms protein. Signi®cant inhibition of complex formation was apparent with as little as 20 mM (lane 4). Thus, these results exclude the possibility that the observed interactions and their disruption by UCS15A, are GST-dependent. Similarly to the previous in vitro system (utilizing two GST fusion proteins), in the one GST fusion protein in vitro system, the drug also appeared not to bind directly to the SH3 domain of Fyn (Figure 9a, right panel) . Fyn-SH3 beads were incubated with dierent concentrations of the drug (Figure 9a, right panel, lanes 2 ± 4) and the unbound drug was washed o the beads (for details see Materials and methods). The drug-treated beads were then incubated with total cell lysates, and tested for their ability to bind to endogenous Sam68. Washed Fyn-SH3 beads remained competent to bind Sam68 even when they had been pre-treated with as much as 500 mM of the drug (Figure 9a, right panel, lane 4) . However, as expected, if the beads were not washed after incubating with the drug, they eectively blocked the ability of Fyn SH3 to interact with Sam68 in cell lysates (Figure 9a, right hand panel, lane 1) . This result suggested that UCS15A probably did not interact with the SH3 domain of Fyn. The converse experiment consisted of treatment of cell lysates with UCS15A, followed by removal of the unbound drug by dierent methods such as ultra®ltration (Figure 9b, lanes 3 ± 5) or dialysis (Figure 9b, lanes 6 ± 8) . Subsequent anity precipitation with Fyn-SH3 agarose beads revealed that the Sam68 from the drug-pretreated and washed lysates were incapable of binding to Fyn-SH3 agarose beads (Figure 9b, lanes 3 ± 8) , similar to the unwashed beads (Figure 9b, lanes 1 ± 2) . These results were consistent with those obtained using the two GSTfusion protein in vitro system (Figures 7 and 8 ) and led to the conclusion that UCS15A bound to the prolinerich domain of Sam68, thereby blocking its interaction with the Fyn-SH3 domain.
Discussion
The present studies have led to the following conclusions: ®rst, UCS15A, a non-tyrosine kinase inhibitor, inhibited SH3-mediated protein ± protein interactions in vivo in a widespread and perhaps, universal manner. Second, not only typical SH3-mediated protein ± protein interactions such as Src ± Sam68, Sam68 ± Grb2, Sam68 ± PLCg, cortactin ± ZO1 and Grb2 ± Sos but also atypical SH3-mediated protein ± protein interactions such as Grb2 ± Gab1 were blocked by UCS15A. Third, UCS15A did not exert its inhibitory eects on non-SH3-mediated protein ± protein interactions found in the E-cadherin/a-/b-catenin complex or SH2-mediated protein ± protein interactions found in the Grb2 ± EFGR complex. Fourth, inhibition of SH3-mediated protein ± protein interactions by UCS15A could be recreated in vitro, suggesting that UCS15A exerted its inhibitory eects by acting directly on the SH3-mediated protein ± protein complex. Fifth, UCS15A mediated its eects probably by binding directly to proline-rich domain containing proteins such as Sam68. Taken together, the results of this study suggest that UCS15A possesses the unique ability to bind to proline-rich domain containing proteins and block their subsequent interaction with SH3 domain containing proteins. In this regard, UCS15A is the ®rst and only example of a non-peptide, small molecule signal transduction inhibitor whose unprecedented mode of action involves blocking SH3-mediated protein ± protein interactions. The current studies help clarify the mechanism of action of UCS15A in inhibiting the bone resorption activity of osteoclasts (Sharma et al., 2001 ). In addition, given the importance of SH3-mediated protein ± protein interactions in human disease (reviewed in Smithgall, 1995; Dalgarno et To investigate the eect of UCS15A on the proline-rich domain containing Sam68, HCT116 cell lysates were incubated at 378C for 6 h with the concentrations of UCS15A indicated at the top of the each lane. Unbound UCS15A was removed by ultra®ltration (lanes 3 ± 5) or dialysis (lanes 6 ± 8), as indicated at the top of the lanes. After removal of unbound UCS15A, cell lysates were incubated with Fyn-SH3 AC and the anity precipitated Sam68 was detected by Western blotting with anti-Sam68 antibody. Position of migration of Sam68 is indicated by an arrow in the margins of the autoradiograms UCS15A disrupts SH3-mediated protein interactions C Oneyama et al al., 1997) it is likely that UCS15A or improved versions of this drug may ®nd widespread applications in the treatment of various human diseases. It is interesting that UCS15A, which the present studies suggest is a widespread blocker of SH3-mediated protein ± protein interactions, was isolated as an agent that could reverse the growth inhibition imposed by the ectopic expression of an activated Src gene in yeast (Sharma et al., 2001) . This suggests that generalized disruption of SH3-mediated protein ± protein interactions is not detrimental to the growth of yeast and is surprising since this interaction is so commonplace in biological systems. However, the results of the genome sequencing of Saccharomyces cerivisiae suggest that this organism has only 25 genes that encode for SH3-domain containing proteins (Rubin et al., 2000) . Moreover, many SH3 interactions, especially those mediating intramolecular protein ± protein interactions, serve to negatively regulate signal transduction (Franz et al., 1989; Jackson and Baltimore, 1989; Seidel-Dugan et al., 1992; Mayer and Baltimore, 1994; Yamashita et al., 1996; Andreotti et al., 1997; reviewed in Mano, 1999; Kay et al., 2000) . Taken together, the current studies suggest that, at least in yeast, SH3-mediated protein ± protein interaction may be dispensable for the viability of the organism. In addition, since UCS15A disrupts Src SH3 domain-mediated interactions, it might be expected to activate c-Src in vitro. This would be consistent with previous ®ndings that suggest that intramolecular interactions mediated by both the SH2 and SH3 domain of c-Src regulate it activity (reviewed in Nguyen and Lim, 1997; Schwartzberg, 1998) . Contrary to expectation, the present studies suggest that UCS15A, while disrupting Src SH3 domain-mediated interactions, had no eect on its kinase activity (Figure 2 ). While the reason for this discrepancy is presently unclear, it is possible that the intramolecular SH3 interactions that operate in regulating c-Src are much stronger than the intermolecular SH3-mediated protein ± protein interactions that UCS15A appears capable of disrupting. Alternatively, given the speci®city of UCS15A for SH3 mediated interactions, it is possible that the drug is unable to overcome the combined SH2-and SH3-mediated intramolecular interactions that keep c-Src in a closed, inactive complex.
Despite the widespread ability of UCS15A to disrupt SH3-mediated protein ± protein interactions, some differences in the potency of the drug towards dierent SH3-mediated interactions were noted. Due to the nonquantitative nature of the assays employed, strict comparisons in the drug's ability to inhibit diverse SH3-mediated interactions are dicult. However, some generalizations are possible. UCS15A very eectively disrupted the interaction between Src and Sam68 (Figure 1 ) whereas it was somewhat less eective in disrupting the Sam68 ± Grb2, Sam68 ± PLCg (Figure 3 ), Cortactin ± ZO1, Grb2 ± Sos1 and Grb2 ± Gab1 (Figure  4) complexes. Previous studies using degenerate peptide libraries and phage display libraries have suggested that even though the binding of SH3 domains to their ligands is generally characterized by relatively low anity, they, nonetheless, exhibit distinct binding preferences (Yu et al., 1994; Birge et al., 1996) and that SH3 domains of highly related protein such as cSrc and c-Yes have distinct speci®cities with respect to their interacting partners (Summy et al., 2000) . In this regard, the dierences in potency of UCS15A may be related to the dierences in the binding anities between these proteins, or the preference of UCS15A for speci®c SH3-ligand complexes.
UCS15A was capable of blocking SH3-mediated protein ± protein interactions both in vivo as well as in vitro, albeit with dierent eciency (Figures 1b and 7c,  respectively) . Interestingly, however, UCS15A failed to disrupt SH3-mediated interactions in vitro, once complexes were formed (Figure 8 ). The concentration of UCS15A required for blocking SH3-mediated protein ± protein interactions in vitro (100 ± 200 mM) was approximately 100 times greater than the concentrations of the drug required for in vivo ecacy (1 mM). This surprising discrepancy is counter-intuitive, since it would be expected that UCS15A would have many more binding sites in vivo as compared to in vitro. Although the reasons for this dierence are unclear at the present time, several possibilities could account for the observed dierences. First, it is possible that in the in vitro system there are more SH3-proline rich interacting sites since relatively high concentrations of the isolated recombinant domains were used in the in vitro assay system. Second, other studies have shown that Kd values of synthetic peptides interacting with SH3 domains was in the order of 1 ± 100 mM whereas Kd values for full-length proteins were signi®cantly lower, around 200 nM (reviewed in Kay et al., 2000) . These values agree well with the dierences in the eectiveness of UCS15A to disrupt SH3-mediated interactions in vivo, where full-length proteins were involved, vs in vitro, where isolated recombinant domains were involved. Third, in the in vitro assay system, the isolated proline-rich domain-containing peptide, Sam68DC, probably has a rigid structure with minimal conformational¯exibility. In vivo, UCS15A binding to Sam68 may induce a conformational change in the native protein that may mask the proline-rich SH3 binding domain and prevent further binding to SH3 domains. However, in vitro no such masking would be possible and hence a larger concentration of drug may be required to maintain the blockade. Since it is well established that proline-rich interactions are generally low-anity interaction with very high o-rates, very high concentrations of drug may be required in vitro to keep the complex apart. In vivo the situation may be dierent due to alterations in the folding of the protein upon binding of the drug. Consistent with this idea, a signi®cant dierence in the ability of UCS15A to disrupt SH3-mediated interactions in vitro was observed, depending on whether the full-length Sam68 protein or a fragment of Sam68 containing just two proline-rich domains (Sam68DC) was used. UCS15A was able to block the interaction of the Fyn-SH3 domain to full length Sam68 at a lower concentration (20 mM) of the drug than was required to block the interaction of Fyn-SH3 with Sam68DC (100 ± 200 mM; Figures 7c and 9a) .
Fourth, the concept of compartmentalization of the interacting partners in vivo has been invoked as a mechanism to enhance the inherent lack of speci®city in SH3-mediated interactions (reviewed in Ladbury and Arold, 2000; Mayer, 2001) . It is possible that in vivo UCS15A may have access to such a compartment in which the SH3-proline rich domains reside, thereby dramatically increasing the eective concentration of the drug in the viscinity of the SH3-mediated protein ± protein complex. In this regard, it is interesting to note that previous studies have suggested that SH3 domains direct signaling complexes to distinct intracellular locations (Bar-Sagi et al., 1993) and suggest that spatiotemporal distribution of signaling complexes may have profound albeit poorly understood implications in signaling transduction (reviewed in Hunter, 2000) . Our current studies can not distinguish among the abovementioned possibilities.
Taken together, the present studies prove that nonpeptide based, small molecule inhibitors of SH3-mediated protein ± protein interactions are feasible. No such inhibitors had been reported thus far, and this was believed to be dicult to achieve, due to the extended nature of the binding site (390 A Ê 2 ) that is involved in SH3-proline rich domain interactions (reviewed in Dalgarno et al., 1997) , as well as the apparent lack of speci®city shown by SH3 domains (reviewed in Ladbury and Arold, 2000) . The challenge for the future will be to build onto the UCS15A backbone, chemical groups that will enhance the selectivity of the agent to block speci®c SH3-proline rich interactions. This should be greatly aided by the wealth of detailed structural information on liganded SH3 domains determined by X-ray crystallography and NMR methods (reviewed in Dalgarno et al., 1997) and the determination of the costructure of UCS15A with proline-rich domain(s). Such, structure-based drug design should result in the development of secondgeneration UCS15A derivatives with greatly improved selectivity towards speci®c SH3-proline rich domain interactions that may be clinically useful in the treatment of various diseases.
Immunoprecipitation and immunoblotting analyses
For immunoprecipitation analyses, 2-day-old, sub-con¯uent cells (two 100 mm dishes per treatment) were treated with dierent concentrations (ranging from 0 ± 30 mM) of UCS15A for 2 h. At the end of the treatment period, cells were placed on ice, scraped and collected in their own medium. Cell pellets were lysed by the addition of 1 ml of ice-cold Triton X-100/NP40 lysis buer as described previously (Sharma et al., 2001) . Lysates were clari®ed by microcentrifugation (15 000 r.p.m. for 30 min at 48C). The protein concentration of clari®ed lysates were quantitated and equal amounts of total cell protein were immunoprecipitated overnight with the indicated antibodies (3 mg of Src antibody, 2 mg of PLCg antibody, 2 mg of Grb2 antibody, 3 mg of cortactin antibody and 1.5 mg of E-cadherin antibody). Immunoprecipitates were collected on Protein A/G beads (30 mls per immunoprecipitation). Beads were washed three times in lysis buer, resuspended in 35 ml of Lammli's sample buer and resolved on 6, 7.5 or 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes, immunoblotted with the indicated antibodies, subjected to chemiluminescent detection and, in some cases, the blots were stripped and reprobed as described previously (Sharma et al., 2001) .
To examine the mode of interaction of Sam68 with Fyn, PLCg and Grb2, HCT116 cells were extracted with Triton X-100/NP40 lysis buer as described above. Cell lysates were incubated at 48C, overnight with the indicated protein domains conjugated to agarose.
For the detection of phosphorylated proteins, membranes were incubated with HRP-conjugated phosphotyrosine antibody (1 : 5000 dilution) for 2 h. For the detection of GST fusion proteins, membranes were incubated with HRPconjugated GST antibody (1 : 1000 dilution) for 4 h. For the detection of Sam68, ZO1, cortactin, Sos1, EGFR, Gab-1, a-catenin and b-catenin, membranes were incubated with the indicated antibodies (1 : 1000 dilution) for 2 h followed by secondary antibodies (1 : 4000 dilution).
In vitro SH3-proline rich domain interaction assay
To examine the eect of UCS15A on the association of Sam68 with Fyn-SH3, HCT116 cells were used 2 days after plating on 10 mm dishes. Cells were washed once in PBS and UCS15A disrupts SH3-mediated protein interactions C Oneyama et al incubated with 4 ml of ice-cold reticulocyte swelling buer (RSB: 10 mM Tris; pH 7.6; 10 mM NaCl; 1.5 mM MgCl 2 ). Cells were allowed to swell on ice for 10 min, at the end of which they were scraped into a 7 ml Dounce homogenizer and ruptured by 40 strokes of a tight-®tting pestle. Cell lysates were clari®ed by centrifugation at 15 000 r.p.m. for 30 min at 48C. Clari®ed lysates were divided into 1 ml aliquots. To each aliquot was added 0, 0.1 or 0.5 mM of UCS15A and the samples were incubated at 378C for 6 h. Subsequently, 5 ml of Fyn-SH3 AC slurry was added and the samples were incubated at 48C, overnight.
To determine whether UCS15A bound to Fyn-SH3 AC or to Sam68, 5 ml of Fyn-SH3 AC beads were ®rst incubated with 0, 0.1 or 0.5 mM of UCS15A at 378C for 6 h. The beads were washed with RSB buer, two times, to remove unbound UCS15A. The washed beads were then incubated at 48C, overnight, with RSB cell lysates. To examine the binding to UCS15A to proline-rich domain-containing Sam68, RSB cell lysates (as described above) were initially incubated with 0, 0.1 or 0.5 mM of UCS15A at 378C for 6 h. Unbound UCS15A was removed from the cell lysates by two alternative procedures, ultra®ltration and dialysis. For ultra®ltration, cell lysates were subjected to Centricon 10 (Amicon) centrifugation at 6000 r.p.m., for 30 min at 48C. This resulted in a decrease in the volume, which was replaced by 1 ml of RSB buer, followed by repeated centrifugation. Such washes were done four times. For dialysis, cell lysates were put into the Slide-A-Lyzer Dialysis Cassettes (PIERCE) and dialyzed at 48C for 3 h against 3 L of RSB buer. After removing the unbound UCS15A by one of these two methods, cell lysates were incubated with 5 ml of Fyn-SH3 AC at 48C, overnight.
The second in vitro system consisted of a two protein system. The two proteins used in this in vitro assay system consisted of the recombinant protein, Sam68DC, which was used at a concentration of 0.5 mg per reaction and Fyn-SH3 AC beads (5 ml of resuspended beads per reaction). Each reaction was done in 1 ml of binding buer (10 mM Tris; pH 7.6, 10 mM NaCl, 1.5 mM MgCl 2 , 0.1% BSA). Binding of UCS15A to the dierent protein modules (Fyn-SH3 AC or Sam68DC) was carried out for 6 h either at 08C or 258C as indicated in Figures 7 and 8 . The concentrations of UCS15A that were used, ranged from 0 to 500 mM as indicated in Figures 7 and 8 . In the experiment shown in Figure 7a , following binding of the drug to a protein module, the complementary protein module was added to the reaction and protein ± protein interaction was allowed to proceed overnight at 48C. To determine which protein module bound to UCS15A (Figure 8b ), various concentrations of UCS15A were added to the dierent protein modules (Fyn-SH3 or Sam68DC) and incubated for 6 h at 48C. Subsequently, unbound UCS15A was removed by centrifugation of the samples through a Centricon 10 (Amicon) ®lter for 40 min at 6000 r.p.m. at 48C. After removal of unbound UCS15A, each protein was incubated with its complementary protein, conjugated to agarose beads and incubated overnight at 48C. Subsequently, the beads were washed three times in Triton X-100/NP40 lysis buer, resuspended in 30 ml of Lammli's sample buer and the proteins were resolved by electrophoresis on 7.5% or 10% SDS-polyacrylamide gels. Separated proteins were transferred to nitrocellulose membranes, immunoblotted with the indicated antibodies and subjected to chemiluminescent detection.
Src kinase assays
Lysates of HCT116 cells from a 100 mm dish were used and Src kinase assay were performed as described previously (Zhu et al., 1998; Sharma et al., 2001) .
